Claire N. Harrison

TL;DR: The safety profile of pacritinib in patients with cytopenic myelofibrosis was described in the Phase 2 PAC203 and Phase 3 PERSIST-2 studies as mentioned in this paper .

TL;DR: An explosion of interest in this field followed the description of the JAK2 V617F mutation in 2005, and very rapidly the first trials of JAK inhibitors as potential therapies have followed, and promising data from studies with histone deacetylase inhibitors (HDAC), inhibitors of mammalian target of rapamycin (mTOR) and the thalidomide analogue pomalidomides are all described.

TL;DR: It is hypothesised that a reduction in Treg frequency and function would correlate with the expansion of a clonal LGL population in certain patients taking dasatinib, and significantly reduced phosphorylation of ZAP70 compared with the non d asatinib group in CD3+ cells, CD4+ cells and Tregs, following H2O2 stimulation.